Dibekacin

Dibekacin
Clinical data
Trade namesPanimycin, Tokocin
Other names3',4'-Dideoxykanamycin B
AHFS/Drugs.comInternational Drug Names
ATC code
Identifiers
  • (2S,3R,4S,5S,6R)-4-Amino-2-[(1S,2S,3R,4S,6R)-4,6-diamino-3-[(2R,3R,6S)-3-amino-6-(aminomethyl)oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-6-(hydroxymethyl)oxane-3,5-diol
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEMBL
PDB ligand
CompTox Dashboard (EPA)
ECHA InfoCard100.047.316
Chemical and physical data
FormulaC18H37N5O8
Molar mass451.521 g·mol−1
3D model (JSmol)
  • C1C[C@H]([C@H](O[C@@H]1CN)O[C@@H]2[C@H](C[C@H]([C@@H]([C@H]2O)O[C@@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)N)O)N)N)N
  • InChI=1S/C18H37N5O8/c19-4-6-1-2-7(20)17(28-6)30-15-8(21)3-9(22)16(14(15)27)31-18-13(26)11(23)12(25)10(5-24)29-18/h6-18,24-27H,1-5,19-23H2/t6-,7+,8-,9+,10+,11-,12+,13+,14-,15+,16-,17+,18+/m0/s1
  • Key:JJCQSGDBDPYCEO-XVZSLQNASA-N

Dibekacin (3',4'-dideoxykanamycin B) is an aminoglycoside antibiotic. It is a semisynthetic derivative of kanamycin developed by Hamao Umezawa and collaborators for Meiji Seika, and first patented in 1970. It has been sold under a wide variety of trade names globally, including Orbicin, Dibekacin Meiji, Panimycin, and Tokocin. Clinical trials have found it to be effective against E. coli, Klebsiella, Enterobacter, Serratia, and Pseudomonas aeruginosa.

It has been used in combination with sulbenicillin.